Advertisement
Advertisement
LFCR
Lifecore Biomedical, Inc. Common Stock
4.29
USDSponsored
-0.11
-2.50%
Sep 24, 15:59 UTC -4
Closed
Pre-Market
4.30
+0.01
+0.23%
LFCR Earnings Reports
Positive Surprise Ratio
LFCR beat 21 of 37 last estimates.
57%
Next Report
Date of Next Report
Feb 05, 2027
Estimate for Q4 26 (Revenue/ EPS)
$38.59M
/-$0.10
Implied change from Q2 26 (Revenue/ EPS)
+12.94%
/-47.37%
Implied change from Q4 25 (Revenue/ EPS)
+5.88%
/+66.67%
Lifecore Biomedical, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, LFCR reported earnings of -0.19 USD per share (EPS) for Q2 26, beating the estimate of -0.22 USD, resulting in a 16.59% surprise. Revenue reached 34.17 million, compared to an expected 32.66 million, with a 4.63% difference. The market reacted with a +2.07% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 7 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 38.59 million USD, implying an decrease of -47.37% EPS, and increase of 12.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Lifecore Biomedical, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Lifecore Biomedical, Inc. Common Stock reported EPS of -$0.19, beating estimates by 16.59%, and revenue of $34.17M, 4.63% above expectations.
How did the market react to Lifecore Biomedical, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.07%, changed from $4.35 before the earnings release to $4.44 the day after.
When is Lifecore Biomedical, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 05, 2027.
What are the forecasts for Lifecore Biomedical, Inc. Common Stock's next earnings report?
Based on 7
analysts, Lifecore Biomedical, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $38.59M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.